Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Timolol Maleate Ophthalmic Gel Forming Solution, 0.25% and 0.5%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Timoptic-XE Ophthalmic Gel Forming Solution, 0.25% and 0.5%, of Bausch Health US, LLC.
Timolol Maleate Ophthalmic Gel Forming Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Alembic has been granted a Competitive Generic Therapies (CGT) designation for this ANDA and it is eligible for 180 days of. CGT exclusivity as it is the first approved ANDA.
Timolol Maleate Ophthalmic Gel Forming Solution, 0.25% and 0.5% has an estimated market size of $ 71 million for twelve months ending June 2020, according to IQVIA. This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies. Alembic has a cumulative total of 134 ANDA approvals (117 final approvals and 17 tentative approvals) from USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1520.00 |
Dr. Reddys Lab | 6260.00 |
Cipla | 1419.55 |
Zydus Lifesciences | 988.00 |
Lupin | 1647.75 |
View more.. |